Ten biotech advancements from Mass General Brigham have been awarded Innovation Discovery Grants. The grants will go toward ongoing development and future commercialization of the innovations, according to a May 3 press release.
Here are the 10 biotech innovations receiving the grant:
- A convection enhanced delivery system: The proposed system aims to address shortcomings in convection enhanced delivery by replacing large delivery tubes with multiple precision micro-cannulas.
- FastLine: A device that places a central line with one hand using ergonomic movements to enable real-time troubleshooting. This allows clinicians to eliminate poorly controlled movements.
- KRAS degraders in cancer: A proposed research program that will use a positive-selection screening platform as a tool to identify protein degraders of Kirsten Rat Sarcoma virus as potential therapeutic agents.
- Tumor immunogenicity in glioblastoma multiforme: A program that has created a new therapeutic that can cross the blood-brain barrier, induce tumor immunogenicity in models of glioblastoma multiforme and other solid cancers. The program aims to change traditional therapy treatment for glioblastoma multiforme.
- MRNA methyltransferase inhibitor: A study that will develop an IND-enabled compound that will target mRNA methyltransferase and validate their effectiveness in cancer therapy.
- Auditory mirror therapy for tinnitus: A technology that provides neuromodulatory therapy for tinnitus treatment. The therapy will be emitted through a wearable pair of headphones.
- Middle-ear pathologies: A project that aims to automate diagnoses of middle-ear pathologies using machine learning to infer details about the middle-ear status from clinical data.
- Small-molecule MMP inhibitors for allergic inflammation: A project aiming to develop small-molecule inhibitors of a specific protein-degrading enzyme as topical therapeutics for atopic dermatitis, asthma and other allergic inflammatory diseases.
- Neutralizing Antibody: A technology that aims to increase the response rate of ovarian cancer to immune checkpoint therapies.
- Circulating microparticle proteins: A blood test that can assess a woman’s risk of placenta accreta spectrum, a potentially life-threatening pregnancy complication, using circulating microparticle proteins.
